US 12,215,098 B2
Solid form, crystalline form, and crystal form a of FXR agonist, and preparation method and application thereof
Xiaolin Li, Shanghai (CN); Peng Li, Shanghai (CN); and Haiying He, Shanghai (CN)
Assigned to CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD., Hebei (CN)
Appl. No. 17/297,271
Filed by CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD., Shijiazhuang (CN)
PCT Filed Nov. 26, 2019, PCT No. PCT/CN2019/120992
§ 371(c)(1), (2) Date May 26, 2021,
PCT Pub. No. WO2020/108485, PCT Pub. Date Jun. 4, 2020.
Claims priority of application No. 201811418346.8 (CN), filed on Nov. 26, 2018.
Prior Publication US 2022/0033391 A1, Feb. 3, 2022
Int. Cl. C07D 413/14 (2006.01); A61P 1/16 (2006.01)
CPC C07D 413/14 (2013.01) [A61P 1/16 (2018.01); C07B 2200/13 (2013.01)] 17 Claims
 
1. A crystalline form of a compound of formula (I), which is crystal form A, characterized by X-ray powder diffraction pattern with characteristic diffraction peaks at the following 2θ angles of 12.72±0.2°, and 25.27±0.2°;

OG Complex Work Unit Chemistry